Glenn Rosen, MD

Consultant of Translational Medicine with Clinical Expertise in Fibrotic and Immuno-Inflammatory Lung Diseases

Dr. Rosen is a globally recognized physician-scientist and executive leader with deep expertise in fibrotic and immuno-inflammatory diseases across both academia and industry. He served as the clinical development lead for Bristol Myers Squibb’s first-generation LPAR antagonist, as well as the discovery lead for a second-generation LPAR antagonist currently in Phase 3 trials. Most recently, Dr. Rosen served as the Chief Translational Officer and Early Clinical Head at Belenos Biosciences, where he specialized in advancing cutting-edge bi-specific antibodies in the I&I therapeutic area.